On November 18, Elevance Health fell 3.03% in Regular Trading, trading at $419.03 per share, with turnover of $41.8232 million.
The move was tied to a proposed tightening in US public health insurance oversight, which the market read as negative for managed care companies.
The latest proposal would increase Medicare Advantage audit frequency, strengthen enrollment reviews, and tighten oversight of Medicaid payment reduction programs, with projected federal savings of nearly $90 billion over 10 years. Managed care peers also weakened, with UnitedHealth falling 4.14%, Humana 5.53%, Centene 4.58%, and Molina Healthcare 4.68%. While Elevance Health recently reaffirmed full-year adjusted EPS of at least $29 and has seen multiple price-target increases, the policy-driven pressure appeared to be the more immediate catalyst for the stock's decline.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)